贝伐珠单抗联合紫杉醇+卡铂治疗晚期卵巢癌患者的疗效分析

Analysis of the efficacy of bevacizumab combined with paclitaxel plus carboplatin in the treatment of patients with advanced ovarian cancer

目的 探讨贝伐珠单抗联合紫杉醇+卡铂治疗晚期卵巢癌患者的疗效。方法 根据治疗方案的不同将126例晚期卵巢癌患者分为化疗组和贝伐珠单抗组,每组63例。治疗前后,检测两组患者血管内皮生长因子(VEGF)、基质金属蛋白酶2(MMP2)、癌胚抗原(CEA)、糖类抗原125(CA125)、CD4^(+)、CD8^(+)、CD3^(+)水平,记录两组患者的不良反应及无进展生存期,比较两组患者的疗效。结果 治疗后,贝伐珠单抗组患者VEGF、MMP2、CEA、CA125、CD8^(+)水平均明显低于化疗组,CD4^(+)、CD3^(+)水平均明显高于化疗组,差异均有统计学意义(P﹤0.01)。贝伐珠单抗组患者总有效率高于化疗组,无进展生存期长于化疗组,差异均有统计学意义(P﹤0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论 贝伐珠单抗联合紫杉醇+卡铂化疗可抑制晚期卵巢癌转移及扩散,明显改善患者的免疫功能,延长无进展生存期,疗效确切。

Objective To investigate the efficacy of bevacizumab combined with paclitaxel plus carboplatin in the treatment of patients with advanced ovarian cancer.Method A total of 126 patients with advanced ovarian cancer were divided into chemotherapy group and bevacizumab group according to different treatment methods,with 63 patients in each group.Before and after the treatment,the levels of vascular endothelial growth factor(VEGF),matrix metalloproteinase 2(MMP2),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),CD4^(+),CD8^(+),and CD3^(+)were detected in the two groups.The adverse events and progression-free survival of the two groups were recorded,and the efficacy was compared.Result After the treatment,the levels of VEGF,MMP2,CEA,CA125,and CD8^(+)in the bevacizumab group were significantly lower than those in the chemotherapy group,while the levels of CD4^(+)and CD3^(+)were significantly higher than those in the chemotherapy group,and the differences were statistically significant(P<0.01).The total effective rate of the bevacizumab group was higher than that of the chemotherapy group,and the progression-free survival was longer than that of the chemotherapy group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse events between the two groups(P>0.05).Conclusion Bevacizumab combined with paclitaxel plus carboplatin chemotherapy could inhibit the metastasis and spread of advanced ovarian cancer,significantly improve patients' immune function,and prolong progression-free survival with definite efficacy.